trans-resveratrol

Phase 2Small molecule

HHuazhong University of Science and Technology

trans-resveratrol is one of 73 small molecule programs targeting Parkinson's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's DiseaseRecruiting

TicsUnknown status

Parkinson's DiseasePhase 2

Recruiting

TicsPreclinical

Unknown status

Competition

Competitive Landscape

114 competitors in Tics

#DrugCompanyPhaseTrials

Sodium Valproate

AstraZeneca

Phase 3

1 2

Priftin

Sanofi

Phase 2

1 3

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

4 4

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 1

54 5

Duvyzat

Italfarmaco

Phase 2

2 6

Dilaudid

RRhodes Pharmaceuticals, L.P.

Phase 2

1 7

CAB LA

GSK

Phase 2

1 8

Taltz

Eli Lilly

Phase 1

1 9

Abexinostat

XXynomic Pharmaceuticals, Inc.

Phase 2

1 10

Cocaine Hydrochloride

NNoden Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Parkinson's Disease

NCT07592767

Clinical

Trials by Indication[1]

Tics1 trial

Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood

Unknown status·HHuazhong University of Science and Technology·N/A·NCT02321176·20 enrolled

Parkinson's Disease1 trial

Multicenter, Randomized, Double Blind, Placebo-Controlled Phase 2a Study, to Evaluate Safety, Tolerability and Pharmacokinetics of Resveratrol (JOTROLTM) in Parkinson's Disease

Recruiting·GGeorgetown University·Phase 2·NCT07592767·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for trans-resveratrol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — trans-resveratrol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for trans-resveratrol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHuazhong University of Science and Technology

trans-resveratrol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Tics1 trial

Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News